Filing identity and reporting period
The supplied filing is Zafgen, Inc.’s Form 10-K for the fiscal year ended December 31, 2014, signed March 24, 2015. It is not identified as a Larimar Therapeutics filing. The annual report includes fourth-quarter 2014 financial data; it is not a standalone Q4 filing.
Business context
Zafgen was a pre-revenue biopharmaceutical company developing beloranib, a twice-weekly injectable MetAP2 inhibitor, primarily for obesity and hyperphagia in Prader-Willi syndrome (PWS), hypothalamic injury-associated obesity (HIAO), and severe obesity in the general population. ZGN-839 and other MetAP2 inhibitors remained preclinical.
- Beloranib’s U.S. Phase 3 PWS trial began in September 2014. The company anticipated six-month data by early Q2 2016 and planned an EU Phase 3 trial for mid-2015.
- A Phase 2b trial for severe obesity in patients with type 2 diabetes began in December 2014; interim six-month results were expected in late 2015 or early 2016.
- A 14-patient Phase 2 HIAO trial reported mean weight loss of 3.4 kg at four weeks and 6.2 kg at eight weeks with beloranib; placebo patients lost a mean 0.3 kg at four weeks. These were early, small-trial results, not evidence of approval or long-term efficacy.
Financial performance and liquidity
Amounts below are in U.S. dollars; financial statement figures are in millions unless otherwise indicated.
| Metric | FY 2014 | FY 2013 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $27.391 | $9.561 |
| General and administrative expense | $8.141 | $4.219 |
| Total operating expense | $35.532 | $13.780 |
| Net loss | $(36.478) | $(14.027) |
| Net loss attributable to common stockholders | $(36.570) | $(14.240) |
| Basic and diluted loss per share | $(3.00) | $(19.53) |
| Cash used in operating activities | $(28.241) | $(15.004) |
- Operating expenses rose $21.752 million year over year, driven mainly by beloranib development and a $7.019 million licensing milestone expense tied to starting the first Phase 3 PWS trial. The milestone included common shares valued at $3.569 million.
- There was no product revenue or profit; margins are not meaningful for this pre-commercial company. The filing reports no clear standalone quarterly margin measure.
- At December 31, 2014, cash and cash equivalents were $58.103 million and marketable securities were $57.359 million, totaling $115.462 million. Working capital was $110.297 million; total assets were $117.519 million.
- Operating cash use increased from $15.004 million to $28.241 million. Investing activities used $57.315 million, principally for marketable securities purchases; financing provided $108.142 million, primarily from the IPO.
- Year-end notes payable were $7.5 million principal, presented as $1.381 million current and $6.177 million long-term net of discount and related accounting adjustments. The loan carried 8.1% stated interest, an effective rate of approximately 14%, and a 6% final payment; it was secured by substantially all personal property other than intellectual property.
- After year-end, a January 2015 follow-on offering generated approximately $129.5 million net proceeds. Management said year-end funds plus offering proceeds were expected to fund operations for at least 18 months; this is an estimate dependent on operating plans and assumptions.
Material changes and unusual items
- R&D expense nearly tripled, from $9.561 million to $27.391 million; G&A increased from $4.219 million to $8.141 million. The Phase 3 milestone, increased manufacturing/preclinical work, trial activity, hiring, and public-company costs were notable drivers.
- The June 2014 IPO raised $102.7 million net, and all preferred shares converted into common stock. The resulting share-count change makes the sharp change in reported loss per share versus 2013 difficult to compare directly.
- The company recorded $0.870 million interest expense, largely related to its 2014 credit facility. It reported a $0.104 million foreign-currency transaction loss and a $0.035 million unrealized loss on marketable securities.
- Q4 2014 operating expenses were $10.664 million and net loss attributable to common stockholders was $10.931 million; the filing reports no quarterly revenue.
Outlook, commentary, and principal risks
Management expected expenses and losses to rise as beloranib advanced through clinical trials and ZGN-839 progressed toward an anticipated mid-2015 IND filing. The company had no approved products, sales organization, or internal manufacturing facilities and relied on contract manufacturers and clinical research organizations.
- Beloranib was the company’s principal clinical-stage asset, leaving the business highly dependent on successful trials, regulatory approval, and eventual commercialization.
- Clinical evidence was preliminary and trial populations were small in completed PWS and HIAO studies. Longer-duration trials were needed; later results could differ. Reported adverse events included sleep disturbance, nausea, vomiting, and other gastrointestinal effects. Two serious thrombotic events in the severe-obesity Phase 2a trial were not attributed to treatment, but the filing noted the need for vigilance.
- Animal studies raised potential concerns including immunosuppression, blood-cell effects, reproductive toxicity, and embryo-fetal malformations. The company required pregnancy precautions and planned continued monitoring; it anticipated a pregnancy contraindication if approved.
- For PWS, primary endpoints depended in part on validation of a caregiver questionnaire; failure or delay could affect trial or filing timelines. Regulators could require additional trials or different evidence.
- Manufacturing processes were not yet validated, supply was outsourced without long-term supply agreements, and delays or quality issues could disrupt trials or commercialization.
- Additional risks included uncertain patient population and reimbursement, competition, intellectual-property and license dependence, potential financing needs beyond the stated runway, and possible limitations on tax-loss carryforwards under Section 382.
Important facts for investors to verify
- Confirm the issuer: the supplied 10-K is for Zafgen, Inc., not Larimar Therapeutics, Inc.
- Check subsequent disclosures for beloranib’s clinical safety, trial status, regulatory path, and whether the stated data expectations were met.
- Reconcile cash burn and liquidity against the January 2015 offering, actual subsequent spending, and the stated 18-month runway estimate.
- Review credit-facility repayment terms, licensing milestones and royalties, and manufacturing supply and validation status.
- Assess the comparability and statistical strength of early clinical results against the larger, longer Phase 2b and Phase 3 trials.